Stable sugammadex composition and product thereof
A stable sugammadex composition in a plastic prefilled syringe addresses the fragility and contamination issues of glass syringes, ensuring long-term stability and ease of use, while being cost-effective and industrially practical.
Patent Information
- Application Number
- PCT/IN2026/050781
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-12
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-19
AI Technical Summary
Existing sugammadex compositions face stability issues due to glass syringes' fragility and susceptibility to contamination, and prior solutions are costly, complex, or not industrially feasible.
A stable sugammadex composition is provided in a plastic prefilled syringe, comprising sugammadex sodium, a pH modifying agent, and a carrier, with a pH between 7 and 8, which is sterilized by radiation and maintains stability for at least 3 months at 20°C to 25°C.
The plastic prefilled syringe ensures long-term stability and ease of use, reducing the risk of contamination and breakage, while being economically viable and industrially feasible.
Smart Images

Figure IMGF000011_0001 
Figure IMGF000016_0001_TABLE 
Figure IMGF000017_0001_TABLE
Abstract
Description
[0001] “STABLE SUGAMMADEX COMPOSITION AND PRODUCT THEREOF” FIELD OF THE INVENTION:
[0002] The present invention relates to medicinal product comprising ready to administer / use sugammadex composition. More particularly the present invention relates to Sugammadex Composition wherein the composition has long term stability at room temperature and is provided in a ready to administer / use prefilled plastic syringe.
[0003] BACKGROUND OF THE INVENTION:
[0004] Sugammadex is a modified gamma cyclodextrin, for the reversal of neuromuscular blockade
[0005] induced by rocuronium bromide and vecuronium bromide in patients undergoing surgery. At present it is commercialized as a sterile, intravenous, injectable composition comprising 100 mg / mL of sugammadex. It is supplied as single-dose vials (glass) containing 200 mg or 500 mg sugammadex.
[0006] As per requirement, the hospital pharmacies have to withdraw the required amount of product in the syringe, label it, cover the syringe to protect medication from contamination and transfer it to the operating room under protective conditions. Any minor error in any of the given step may affect the operating procedure or safety of the patient.
[0007] The US patent 11097023 discloses a pre-filled syringe containing sugammadex. The syringe suitable for this product is said to be a glass syringe. Although a product in glass syringe may have similar stability portfolio as that of glass vial, the glass containers are prone to contamination due to glass particles. It is also fragile and vulnerable to breakage during transport or while handling.
[0008] In the US application 20220273517 sugammadex sodium aqueous solution in an oxygen permeable medical container is disclosed. The medical container is a syringe, and this syringe is in turn packed in an oxygen non-permeable containerfor stability of the product, wherein the oxygen non-permeable container comprises oxygen absorber.
[0009] The prior art discloses several permutation and combinations to arrive at a stable sugammadex product. The solutions are sometimes not feasible due to its costly and breakable solutions or due to its complex procedures or complexities around packaging. The process in the prior art are non-economic, difficult to reproduce therefore industrially not feasible.
[0010] The object of the invention is to provide a stable, economic, easily reproducible, industrially feasible, sage to transport and easy to handle product comprising sugammadex composition.
[0011] SUMMARY OF THE INVENTION:
[0012] In an aspect the present invention relates to Sugammadex Composition wherein the composition has long term stability at room temperature and is provided in a ready to use plastic prefilled syringe.
[0013] According to an aspect, the present invention relates to a prefilled syringe comprising ready to administer sugammadex composition, wherein the prefilled syringe is a plastic prefilled syringe.
[0014] According to another aspect, the present invention relates to a syringe comprising ready to administer sugammadex composition, wherein the composition is stable for at least 3 months when stored at 20°C to 25°C in the said syringe.
[0015] According to yet another aspect, the present invention relates to a composition comprising sugammadex or its pharmaceutically acceptable salt and a carrier, wherein the composition is filled in a syringe having plastic barrel and wherein the composition is stable for at least 3 months when stored at 20°C to 25°C in the said syringe.According to a specific embodiment, the present invention relates to a stable, ready to administer composition comprising sugammadex sodium, a pH modifying agent and a carrier, wherein pH of the composition is between 7 and 8, and wherein the composition is filled in a syringe having plastic barrel and wherein the composition is stable for at least 3 months when stored at 20°C to 25°C in the said syringe.
[0016] According to an aspect, the present invention relates to a syringe comprising:
[0017] 1. a barrel and tip wherein the tip has an integrated luer lock, and wherein the barrel, tip and the luer lock is made up of plastic material,
[0018] 2. a plunger stopper, and
[0019] 3. a polypropylene plunger rod;
[0020] wherein the syringe further comprises a composition comprising sugammadex sodium and wherein the composition is stable for at least 3 months when stored at 20°C to 25°C in the said syringe.
[0021] According to another aspect, the present invention relates to a syringe comprising:
[0022] 1. a barrel and tip wherein the tip has an integrated luer lock, and wherein the barrel, tip and the luer lock is made up of plastic material,
[0023] 2. a plunger stopper, and
[0024] 3. a polypropylene plunger rod;
[0025] wherein the syringe is sterilized by radiations of at least 20 kGy and wherein the syringe further comprises a composition comprising sugammadex sodium and wherein the composition is stable for at least 3 months when stored at 20°C to 25°C in the said syringe.
[0026] According to an aspect, the present invention relates to the process to prepare composition of the present invention. According to another aspect, the present invention relates to the process to prepare prefilled syringe of the present invention.According to an aspect, the present invention relates to the prefilled syringe of the present invention for use in the treatment of a condition treatable using the composition in the prefilled syringe.
[0027] DESCRIPTION OF THE DRAWINGS:
[0028] Figure 1: HPLC chromatogram of the composition of Example 1 used for analysis in Example 2 with spectra for Sugammadex Impurities.
[0029] DESCRIPTION OF THE INVENTION:
[0030] The present invention describes in particular the preferred and optional embodiments so that the various aspects therein can be more clearly understood and appreciated. The present invention is not limited to the specific features described herein below. Any skilled person will appreciate the extent to which such embodiments could be extrapolated in practice.
[0031] The invention is capable of other embodiments and of being practiced or carried out in various ways. The materials described as making up the various elements of the invention are intended to be illustrative and not restrictive. Many suitable materials that would perform the same or a similar function as the materials described herein are intended to be embraced within the scope of the invention. The term "syringe" or "prefilled syringe" or “plastic prefilled syringe” used herein interchangeably relates and means to the syringe of the present invention which is filled with composition comprising sugammadex.
[0032] The present invention relates to a medicinal product. The medicinal product of the present invention is a pre-filled syringe. The syringe is filled with ready to administer composition comprising sugammadex or pharmaceutically acceptable salt thereof.
[0033] The composition of the present invention comprises sugammadex or its pharmaceutically acceptable salt. The composition preferably comprises sugammadex sodium. The concentration of sugammadex in the prefilled syringe is between about 80 mg / mL and 250 mg / mL. In an embodiment the concentration isbetween about 80 mg / mL and 150 mg / mL. In a preferred embodiment the concentration is about 100 mg / mL.
[0034] According to an embodiment, the composition of the present invention may further comprise a carrier and / or a tonicity agent.
[0035] The composition is preferably an aqueous solution with water as carrier.
[0036] In a preferred embodiment water is distilled water or a sterile water such as water for injection (WFI).
[0037] The composition may be a non-aqueous solution with pharmaceutically acceptable organic solvents as a carrier. Non-limiting examples of non-aqueous carriers include ethanol, sugar alcohols, dimethyl sulfoxide, polyvinylpyrrolidone and polyethylene glycols.
[0038] The tonicity agent may be added to the composition of present invention to maintain the osmolality of the composition equivalent to the osmolality of the bodily fluids, which may be about 300 milliosmoles per liter (mOsm / L). Some non-limiting examples of tonicity agent are sodium chloride, mannitol and dextrose. The concentration of the tonicity agent is adjusted as per the requirement of the composition to maintain the osmolality. The skilled person is well aware of the ways to adjust the concentration and has knowledge to calculate the amount required to reach the required osmolality.
[0039] According to an embodiment, the composition of the present invention is devoid of tonicity agent.
[0040] The hydrogen ion concentration of the composition affects the stability of active ingredient. It is necessary to adjust and maintain the pH of the composition to the specific level at which the active ingredient is stable. The pH of the composition of the present invention is typically between 7 and 8.
[0041] In an embodiment, the composition of present invention may further comprise one or more pH modifying agent and / or a buffer.The non-limiting examples of pH modifying agent are hydrochloric acid, tartaric acid, citric acid, acetic acid, nitric acid, sulfuric acid, ascorbic acid, lactic acid, malic acid, maleic acid, fumaric acid, phosphoric acid, succinic acid, sodium hydroxide and their mixtures. The pH modifying agent may be used as buffer.
[0042] The composition of the present invention is prepared by the processes known in the art. In an embodiment the composition is prepared under sterile conditions.
[0043] In one embodiment, the process to prepare composition may comprise a step of adding sugammadex or its pharmaceutically acceptable salt to the inert excipient solution and adjusting the pH. In another embodiment, the process to prepare composition may comprise a step of adding sugammadex or its pharmaceutically acceptable salt to the inert, pH adjusted excipient solution.
[0044] In an aspect the composition when prepared has particular specification, which is an ‘initial specification’.
[0045] According to an embodiment, the initial specification of the composition of the present invention includes that it is clear, colorless to slightly yellow-brown solution, isotonic, having pH between 7 and 8. Initial analysis indicates total impurities in the composition to be less than 2% and the sugammadex assay of more than 98%.
[0046] In an aspect, the composition of present invention is stable.
[0047] For the purpose of this invention the term ‘stable’ means that composition of sugammadex in the medicinal product has specifications that exhibit acceptable variations as compared to ‘initial specification’ after storing it for specified period for which it is said to be stable.
[0048] In an embodiment, the composition of the present invention is stable for at least 3 months. In another embodiment, the composition of the present invention is stablefor at least 6 months or at least 9 months, or at least 12 months, or at least 15 months, or at least 18 months or at least 24 months or at least 36 months.
[0049] In yet another embodiment, the composition of the present invention is stable for at least 24 months.
[0050] In another embodiment, the composition of the present invention is stable for at least 36 months.
[0051] According to an embodiment, the medicinal product of the present invention is obtained when the composition with ‘initial specifications’ is filled in a syringe. The skilled person has a knowledge and understanding about the methods of transferring the composition to the syringe, which may include highly sterile conditions.
[0052] Optionally the medicinal product of the present invention may be terminally sterilized.
[0053] In an embodiment the medicinal product of the present invention is terminally sterilized at 121 °C. for at least 15 minutes.
[0054] According to an embodiment, the syringe of the present invention is a plastic syringe. It is well within the understanding of the skilled person that the syringe has components such as barrel with a tip, a plunger rod and a plunger stopper that is fixed on top of the plunger rod. The syringe of the present invention may be integrated with a luer lock and optionally may have a tip cap that may either slid over the tip of the syringe or remain fixed on to the luer lock of the syringe.
[0055] In an embodiment, the barrel and tip and luer lock, if present are independently made up of material such as cyclic olefin copolymer (COC), polypropylene or cyclic olefin monopolymer (COP).In a preferred embodiment, the barrel and tip and luer lock, if present are made up of COC material. Plunger stopper may be a rubber stopper, preferably comprising a halobutyl rubber and the plunger rod may be made up of a plastic material such as polypropylene.
[0056] The syringe of the present invention is sterile. There are several methods of sterilization of a syringe including high temperature sterilization, under pressure sterilization, sterilization using combination of heat and pressure or sterilization using radiations.
[0057] In a preferred embodiment, the syringe of present invention is sterilized using radiations, wherein the radiations may include X-rays, gamma rays, electron beam, ultraviolet or infrared radiations.
[0058] The process sterilization is as known in the prior art, for example sterilization using X-rays is carried out as per ISO 11137 using the instruments known to the skilled person. In an embodiment, the syringe of the present invention is sterilized using X-rays, which is an effective and economic process as compared to the other known processes.
[0059] In an embodiment, the syringe of the present invention is sterilized using about 20 kGy to about 50 kGy X-ray radiations.
[0060] In an aspect, the medicinal product of the present invention is stable.
[0061] The stability of the medicinal product is construed as the stability of the composition of sugammadex filled in the syringe. When the medicinal product comprising sugammadex composition is stored at specified conditions, the specification of the composition after certain period varies less than or equal to the acceptable limits.According to an embodiment, the medicinal product of the present invention is stable for at least 1 month.
[0062] According to another embodiment, the medicinal product of the present invention is stable for at least 3 months.
[0063] According to yet another embodiment, the medicinal product of the present invention is stable for at least 6 months.
[0064] According to an embodiment, the medicinal product of the present invention is stable for at least 12 months.
[0065] According to another embodiment, the medicinal product of the present invention is stable for at least 15 months.
[0066] According to yet another embodiment, the medicinal product of the present invention is stable for at least 18 months.
[0067] According to another embodiment, the medicinal product of the present invention is stable for at least 24 months.
[0068] According to yet another embodiment, the medicinal product of the present invention is stable for at least 36 months.
[0069] It would be appreciated by the skilled person that the duration for which the product is said to be stable or tested for stability is known as ‘stability period’.
[0070] In an embodiment of the present invention, the stability period is at least 1 month, at least 3 months, at least 6 months, at least 12 months, at least 15 months, at least 18 months, at least 24 months or at least 36 months.In an aspect, the specified condition under which the medicinal product is said to be stable includes temperature of from about 2°C to about 40°C, or from about 20°C to about 25°C, or from about 25°C to about 30°C or from about 30°C to about 35°C or from about 35°C to about 40°C; with relative humidity (RH) of from 25% to 75% and presence or absence of oxygen.
[0071] For the purpose of present invention, the acceptable variation as compared to the ‘initial specification’ is the variation in assay or variation in the amounts of total impurities present in the composition. The acceptable limit of total impurities when assayed after stability period is less than 6%.
[0072] In an embodiment, the acceptable limit of total impurities is less than 5% or less than 3% or less than 2% or less than 1%.
[0073] In another embodiment, the acceptable limit of total impurities is not more than 2%.
[0074] It will be within the understanding of the person skilled in the art that the total impurities amount obtained by addition of the percentage of every impurity including but not limited to know and unknown impurities and related substances. The percentage of impurities is determined using the methods known to the skilled person. Such methods may include high pressure liquid chromatography methods.
[0075] There are several possible impurities that may form in sugammadex sodium composition. Some of the known impurities include mono-sulfoxide epimer 1 and epimer 2 of sugammadex, the structure of which are as given below:
[0076]
[0077] The other possible impurities may include mono thio impurity (6-deoxy-6-thioheptakis (6-deoxy-6-(2-carboxyethyl) thio )-gammacyclodextrin), mono hydroxy sugammadex sodium (Heptakis(6-deoxy-6-(2-carboxyethyl) thio)-gamma-cyclodextrin sodium salt) or other such process related or degradation impurities. Apart from these known impurities, there is possibility of forming unknown impurities, which may be identified by their analytical data. For example, in the present invention a HPLC at retention time 1.02 gives an impurity peak which is not more than 0.25% in the total composition after stability period.
[0078] For the purpose of the present invention, the variation in the assay of active ingredient, sugammadex in the present case may not vary by more than 10% of the initial assay.According to an aspect, the assay of sugammadex may not vary by more than 8% or by more than 6% or by more than 5% or by more than 4% or by more than 3%.
[0079] It will be understood by the skilled person that the variation in assay may be less to more than the initial assay. That means the assay of sugammadex may decrease by 3% or increase by 3% at the end of stability period.
[0080] The medicinal product the present invention may optionally wrapped in a secondary packing. The secondary packing may be a polymeric bag packing, box or carton packing or a blister packing. Optionally an oxygen absorber may be placed in the secondary packing.
[0081] In an embodiment, the medicinal product of the present invention is placed in a secondary packing under inert conditions.
[0082] According to an embodiment, the present invention relates to a stable medicinal product comprising sugammadex composition.
[0083] According to another embodiment, the present invention relates to a stable medicinal product comprising sugammadex composition, wherein the medicinal product is a syringe.
[0084] According to yet another embodiment, the present invention relates to a stable medicinal product comprising sugammadex composition, wherein the medicinal product is a syringe, and wherein the barrel and the tip of the syringe is made up of plastic material.
[0085] According to yet another embodiment, the present invention relates to a stable medicinal product comprising sugammadex composition, wherein the medicinal product is a syringe, and wherein the barrel and the tip of the syringe is made up of plastic material.According to an embodiment, the present invention relates to a syringe comprising a barrel and tip of plastic material, a rubber plunger stopper and plunger rod made up of polypropylene, wherein the syringe optionally comprises a luer lock and a tip cap and wherein the syringe is filled with sugammadex composition.
[0086] According to an embodiment, the volume of the syringe may be from 1 mL to 10 mL.
[0087] The volume may be preferably from 1 mL to 5 mL.
[0088] In a particular embodiment, the volume of the prefilled syringe of the present invention is 2 mL and 5 mL.
[0089] It will be appreciated by the person skilled in the art to arrive at higher volume composition based on the per milliliter (mL) concentration of sugammadex given above.
[0090] According to an embodiment, the present invention relates to a syringe comprising:
[0091] 1. a barrel and tip of plastic material,
[0092] 2. a plunger stopper and
[0093] 3. plunger rod made up of polypropylene,
[0094] wherein the syringe optionally comprises a luer lock and a tip cap and wherein the syringe is filled with sugammadex composition.
[0095] According to another embodiment, the present invention relates to a syringe comprising:
[0096] 1. a barrel and tip of plastic material,
[0097] 2. a plunger stopper and
[0098] 3. plunger rod made up of polypropylene,
[0099] wherein the syringe is filled with sugammadex composition, and wherein the composition is stable at 20°C to 25°C for at least 3 months.According to another embodiment, the present invention relates to a syringe comprising:
[0100] 1. a barrel and tip of plastic material,
[0101] 2. a plunger stopper and
[0102] 3. plunger rod made up of polypropylene,
[0103] wherein the syringe is filled with sugammadex composition, and wherein the composition is stable at 25°C to 30°C for at least 3 months.
[0104] According to another embodiment, the present invention relates to a syringe comprising:
[0105] 1. a barrel and tip of plastic material,
[0106] 2. a plunger stopper and
[0107] 3. plunger rod made up of polypropylene,
[0108] wherein the syringe is filled with sugammadex composition, and wherein the composition is stable at 40°C for at least 1 month.
[0109] According to another embodiment, the present invention relates to a syringe comprising:
[0110] 1. a barrel and tip of plastic material,
[0111] 2. a plunger stopper and
[0112] 3. plunger rod made up of polypropylene,
[0113] wherein the syringe is filled with sugammadex composition, and wherein the total impurities present in the composition is not more than 5% when stored for at least 1 month.
[0114] According to yet another embodiment, the present invention relates to a syringe comprising:
[0115] 1. a barrel and tip wherein the tip has an integrated luer lock, and wherein the barrel, tip and the luer lock is made up of cyclic olefin copolymer (COC) material,
[0116] 2. a plunger stopper, and
[0117] 3. a polypropylene plunger rod;wherein the syringe is sterilized by radiations of at least 20 kGy,
[0118] wherein the syringe is filled with a composition comprising sugammadex sodium, and wherein the composition is stable for at least 6 months when stored at 2°C to 8°C in the said syringe.
[0119] According to another embodiment, the present invention relates to a syringe comprising:
[0120] 1. a barrel and tip wherein the tip has an integrated luer lock, and wherein the barrel, tip and the luer lock is made up of cyclic olefin copolymer (COC) material,
[0121] 2. a plunger stopper, and
[0122] 3. a polypropylene plunger rod;
[0123] wherein the syringe is sterilized by radiations of at least 20 kGy,
[0124] wherein the syringe is filled with a composition comprising sugammadex sodium, and wherein the composition is stable for at least 3 months when stored at 25°C to 30°C in the said syringe.
[0125] According to another embodiment, the present invention relates to a syringe comprising:
[0126] 1. a barrel and tip wherein the tip has an integrated luer lock, and wherein the barrel, tip and the luer lock is made up of cyclic olefin copolymer (COC) material,
[0127] 2. a plunger stopper, and
[0128] 3. a polypropylene plunger rod;
[0129] wherein the syringe is sterilized by radiations of at least 20 kGy,
[0130] wherein the syringe is filled with a composition comprising sugammadex sodium, and wherein the composition is stable for at least 1 month when stored at 40°C in the said syringe.
[0131] According to an embodiment, the present invention relates to a process to prepare a medicinal product comprising sugammadex composition.According to another embodiment, the present invention relates to a method of use of medicinal product disclosed in the present invention.
[0132] At present the sugammadex compositions present in the market are provide in the solution form in vials. The composition has to be withdrawn out in a syringe and administered to the patients in need. The present invention relates to the product that is ready to use. The medicinal product is a syringe comprising sugammadex ready to administer composition.
[0133] According to an embodiment the present invention relates to the method of treatment of patient suffering from the condition treatable by sugammadex composition, wherein the method comprises administering the composition of sugammadex form the medicinal product of the present invention.
[0134] EXAMPLES:
[0135] The examples provided below are for the purpose of demonstrating best mode of invention and do not limit the invention in any manner.
[0136] Example 1:
[0137] Ingredient Amount (mg / ml)
[0138] 108.8 mg / ml (equivalent to 100 mg of Sugammadex Sodium Sugammadex)
[0139] Hydrochloric acid Q.S.to pH- 7.0-8.0
[0140] Sodium Hydroxide Q. S. to pH - 7.0-8.0
[0141] Water for Injection Q.S. to 1 mL
[0142]
[0143] Process:
[0144] a) About 80% of the batch size quantity of water for Injection was collected, nitrogen gas was purged for about 30 minutes to reduce the dissolved oxygen of water to less than 3 ppm;
[0145] b) Sugammadex sodium was added to ‘step a’ and mixed until dissolved.c) pH of the solution in ‘step b)’ was adjusted to around 7.5 using sodium hydroxi de / hydrochloric acid solution
[0146] d) volume of the composition of ‘step c)’ was made 100% with water for Inj .
[0147] and mixed until a homogenous solution was obtained;
[0148] e) the homogeneous solution of ‘step d)’ was aseptically filtered using 0.2 micron (or suitable grade) of filter to obtain filtered composition;
[0149] f) the filtered composition of ‘ step e)’ was aseptically filled in plastic pre-filled syringe (PFS).
[0150] g) The filled PFS was terminally sterilized at 121°C for at least 15 minutes, h) After sterilization, PFS was packed in a blister pack with oxygen absorber.
[0151] Example 2:
[0152] The product of Example 1, with COC PFS of 2 mL was analysed after storage for the period of 3 months and 6 months. The storage conditions: temperature - 25°C +
[0153] 2°C and relative humidity (RH) of 60% + 5.
[0154] Assay of Sugammadex in each millilitre of composition:
[0155] Test Description
[0156] 'Limit: Clear, colorless to slightly yellow-brown Assay by HPLC
[0157] Limit: Each mL contains Sugammadex: lOOmg Schedule solution, free front visible particulate matter, filled
[0158] in pre-filled syringe. - Between 90.0% to 110.0% of label claim I
[0159] initial Clear, colour less solution, free from visible
[0160] 98.7%
[0161] particulate mater filled in prefilled syringe.
[0162] Clear, slightly yellow colour solution free tan
[0163] 3 M
[0164] visible particulate matter filled its PFS, 97,8%
[0165] 6 M Clear, slightly yellow colour solution free from
[0166] visible particulate matter filled in PFS. 98.2%
[0167]
[0168] Impurity and Related Substances Analysis:
[0169] i lesi Related Substances by HPLC i Sulfoxide Impurity Sulfoxide Impuritv I Specified ....identified | unsnecified 1 1 i Sdieduie ‘ : degradation product at RRT Any unspecified Total Imp., rities Epimer ■■ 1
[0170] | 1 Limit: N.M’f 0.8% Limit: NMT 0.8% ; Limit- NMT 0 ?5% 1 Limit: NM3 0.18% | | : Initial 0258% 0.307% 0.042% i 0.010% i 0.6J?% 3M 0246% 0.293% 0.033% \ BQL | 0.581% i 6M 0.279% 0.300%. 0.080% i 0.010% | 0.6?$%
[0171]
[0172] BQL: Below Quantification Limits, NMT : Not More Than
[0173] The product of Example 1 i.e. prefilled syringe of COC with Sugammadex composition therein, when stored at 25°C + 2°C / 60% + 5 relative humidity (RH)
[0174] was found to be stable with approximately 98% of sugammadex assay after 6 months. After stability period of 6 months the total impurities present in the composition were not more than 1%. Epimer - 1 and Epimer - 2 impurities were individually around 0.3% while their limit is NMT 0.8%. The unknown impurity at
[0175] RRT about 1.02 was less than 0.1%, wherein its limit is less than 0.25%. Thus the
[0176] assay and impurities of the composition was found to be within the limits and therefore the product prepared by Example 1 was found to be stable at 25°C + 2°C / 60% + 5 RH.
[0177] Example 3:
[0178] The product of Example 1, with COC PFS of 2 mL was analysed after storage for
[0179] the period of 3 months and 6 months. The storage conditions: 40°C + 2°C / 75% +
[0180] 5RH.
[0181] Assay of Sugammadex in each millilitre of composition:Test Description
[0182] Limit: Clear, colorless to slightly yellow-brown Assay by HPLC
[0183] Linikt Each mL contains Suganimadex: I OOmg Schedule solution, free from visible particulate matter, filled
[0184] in pre-tilled syringe. - Between 90.0% to 110.0% of label claim . . . , c leat-, colour less solution, tree from visible
[0185] Imtial , ... . , 98.7%
[0186] paniculate matter tilled in pretilied synnge.
[0187] Clear, colour less solution, free from visible
[0188] 99.27- paniculate matter filled m prelilied syringe.
[0189] , „ Clear, slidrtlv yellow colour solution free from
[0190] 3 M ' ~ ' 98.17- visible particulate matter lilied rn PFS.
[0191] Clear, slightlv :1 low colour solution free iron'!
[0192] 97.27-
[0193]
[0194] visible particulate matter liked m Pf S.
[0195] Impurity and Related Substances Analysis:
[0196] i Test Related Sabtstanm by HPLC | J : : S..ch, Sulfoxide Impurity 1 Specified unidentified *nvunwecified
[0197] e .d.u.le : Sulfo
[0198] E..xide Impurity .. ’ degradation product at RRT ■ Anj unspcatitd , r0t3f impurities i p .imer - 1 , '
[0199] | | Limit: NMT 0.8%.tp,X- , ^ut t.02 i f -X?U- i Limit: NAT 2.0%
[0200] Limit: NM 1 0.8% Limit: NMT 025'% i Limit: I 0. i 8%
[0201] i Initial 0.258% 0.307% 0.042% i 0010% i 0617%. i I M 0.279% 0333% 0.085% i 0.055% i 0.762% i 3 M 0.275% 0.310% 0.036’% \ BQL i 0.631% | 6M 1 0.499% 0.562% 0.076% i 0012% i 1 :4'%<.
[0202]
[0203] When the stability criteria of product in Example 2 was changed to 40°C + 2°C / 75%
[0204] + 5 RH it was found to be stable with approximately 97% of sugammadex assay
[0205] after 6 months. The total impurities present in the composition were not more than 1.15%. Epimer - 1 and Epimer - 2 impurities were individually around 0.5% and
[0206] 0.6%, respectively while their limit is NMT 0.8%. The unknown impurity at RRT
[0207] about 1.02 was less than 0.1%, wherein its limit is less than 0.25%. Thus, the assay
[0208] and impurities of the composition was found to be within the limits and therefore
[0209] the product prepared by Example 1 was found to be stable at 40°C + 2°C / 75% + 5
[0210] RH, after 6 months.
[0211] The stability results for 3 months and 6 months were similar for 5 mL COC PFS.Figure 1 below shows HPLC analysis of the above product of Example 1 after stability criteria of Example 2, performed using a reversed-phase chromatography system equipped with an ultraviolet (UV) detector set at a wavelength of about 200 nm. The figure shows the epimer 1 and epimer 2 impurities and mono-substituted impurities, as well as unknown impurities and degradation products. The figure further shows a specified unidentified degradation product having a relative retention time (RRT) of about 1.02, corresponding to a retention time of approximately 33.4 minutes.
Claims
We Claim,1. A prefilled syringe comprising ready to administer / use composition comprising sugammadex or pharmaceutically acceptable salt thereof.
2. The prefilled syringe as claimed in claim l is a plastic syringe with a barrel made up of cyclic olefin copolymer (COC), polypropylene or cyclic olefin monopolymer (COP) and the plunger stopper is of halobutyl rubber.
3. The prefilled syringe as claimed in claim 2, wherein the syringe has a. a tip that is integrated with luer lock,b. a plunger stopper, andc. a polypropylene plunger rod4. The prefilled syringe as claimed in claim 3, wherein the syringe is sterilized using about 20 kGy to about 50 kGy of X-ray radiations before filling it with composition comprising sugammadex or pharmaceutically acceptable salt thereof.
5. The prefilled syringe as claimed in claim 4, wherein the composition comprises sugammadex sodium.
6. The prefilled syringe as claimed in claim 5, wherein the concentration of sugammadex in the composition is between about 80 mg / mL and 150 mg / mL.
7. The prefilled syringe as claimed in claim 6, wherein the composition further comprises a pH modifying agent and a carrier.
8. The prefilled syringe as claimed in claim 7, wherein the carrier is water.
9. The prefilled syringe as claimed in claim 7, wherein the pH modifying agent is selected from the group of hydrochloric acid, tartaric acid, citric acid, acetic acid, nitric acid, sulfuric acid, ascorbic acid, lactic acid, malic acid, maleic acid, fumaric acid, phosphoric acid, succinic acid, sodium hydroxide and their mixtures.
10. The prefilled syringe as claimed in claim 9, wherein the pH of the composition is between 7 and 8.
11. The prefilled syringe as claimed in claim 1, wherein the ready to administer / use composition comprising sugammadex is stable for the stability period of at least 3 months.
12. The prefilled syringe as claimed in claim 11, wherein the ready to administer / use composition comprising sugammadex is stable for the stability period of from at least 6 months to up to 36 months.
13. The prefilled syringe as claimed in claim 1, wherein the composition present in the prefilled syringe contains less than 6% total impurities after storage for the stability period at 20°C to 30°C and relative humidity of 25% to 75%.
14. The prefilled syringe as claimed in claim 13, wherein the impurities present in the composition comprise mono-sulfoxide epimer 1 of sugammadex, mono-sulfoxide epimer 2 of sugammadex, mono thio impurity (6-deoxy-6- thioheptakis (6-deoxy-6-(2-carboxyethyl)thio)-gammacyclodextrin), mono hydroxy sugammadex sodium (heptakis(6-deoxy-6-(2-carboxyethyl) thio)- gamma-cyclodextrin sodium salt) or unknown impurities detectable by HPLC.
15. The prefilled syringe as claimed in claim 1, wherein the concentration of sugammadex in the composition present in the prefilled syringe varies not more than 10% after storage for the stability period at 20°C to 30°C and relative humidity of 25% to 75% in the said syringe.
16. The prefilled syringe as claimed in claim 1, wherein the composition exhibits pH variation of not more than ±0.5 after storage for the stability period at 20°C to 30°C and relative humidity of 25% to 75% in the said syringe.
17. The prefilled syringe as claimed in claim 1, wherein the composition exhibits a pH variation of not more than ±0.5 after storage for the stability period at 2°C to 8°C and relative humidity of 25% to 75%.
18. The prefilled syringe as claimed in claim 1, wherein the concentration of sugammadex in the composition present in the prefilled syringe varies not more than 10% after stored for the stability period at 2°C to 8°C and relative humidity of 25% to 75%.
19. The prefilled syringe as claimed in claim 1, wherein the syringe is optionally wrapped in a secondary package.
20. The prefilled syringe as claimed in claim 19, wherein the secondary package is selected from a polymeric bag, a box, a carton or a blister package.
21. The prefilled syringe as claimed in claim 19, wherein the secondary package optionally comprises oxygen absorber.
22. A ready to administer / use composition comprising Sugammadex or pharmaceutically acceptable salt thereof provided in a plastic prefilled syringe.
23. The ready to administer / use composition as claimed in claim 22, wherein the composition comprises sugammadex sodium.
24. The ready to administer / use composition as claimed in claim 22, wherein the concentration of sugammadex in the composition is between about 80 mg / mL and 150 mg / mL.
25. The ready to administer / use composition as claimed in claim 22, wherein the composition further comprises a pH modifying agent and a carrier.
26. The ready to administer / use composition as claimed in claim 25 wherein the carrier is water.
27. The ready to administer / use composition as claimed in claim 25, wherein the pH modifying agent is selected from the group of hydrochloric acid, tartaric acid, citric acid, acetic acid, nitric acid, sulfuric acid, ascorbic acid, lactic acid, malic acid, maleic acid, fumaric acid, phosphoric acid, succinic acid, sodium hydroxide and their mixtures.
28. The ready to administer / use composition as claimed in claim 22, wherein the pH of the composition is between 7 and 8.
29. The ready to administer / use composition as claimed in claim 22, wherein the composition present in the prefilled syringe comprising sugammadex is stable for the stability period of at least 3 months.
30. The ready to administer / use composition as claimed in claim 22, wherein the composition present in the prefilled syringe comprising sugammadex is stable for the stability period of from at least 6 months to up to 36 months.
31. The ready to administer / use composition as claimed in claim 22, wherein the composition present in the prefilled syringe contains less than 6% total impurities after storage for the stability period at 20°C to 30°C and relative humidity of 25% to 75% in the said syringe.
32. The ready to administer / use composition as claimed in claim 31, wherein the impurities present in the composition present in the prefilled syringe comprise mono-sulfoxide epimer 1 of sugammadex, mono-sulfoxide epimer 2 of sugammadex, mono thio impurity (6-deoxy-6-thioheptakis (6-deoxy-6- (2-carboxyethyl)thio)-gammacyclodextrin), mono hydroxy sugammadex sodium (heptakis(6-deoxy-6-(2-carboxyethyl) thio)-gamma-cyclodextrin sodium salt) or unknown impurities detectable by HPLC.
33. The ready to administer / use composition as claimed in claim 22, wherein the composition present in the prefilled syringe exhibits a pH variation of not more than ±0.5 after storage for the stability period at 2°C to 8°C and relative humidity of 25% to 75%.
34. The ready to administer / use composition as claimed in claim 22, wherein the concentration of sugammadex in the composition present in the prefilled syringe varies not more than 10% after stored for the stability period at 2°C to 8°C and relative humidity of 25% to 75%.
35. The ready to administer / use composition as claimed in claim 22, wherein the composition present in the prefilled syringe exhibits a pH variation of not more than ±0.5 after storage for the stability period at 20°C to 30°C and relative humidity of 25% to 75% in the said syringe.
36. The ready to administer / use composition as claimed in claim 22, wherein the concentration of sugammadex in the composition present in the prefilled syringe varies not more than 10% after stored for the stability period at 20°C to 30°C and relative humidity of 25% to 75%.
37. A process to prepare the ready to administer / use composition as claimed in claim 22, wherein the composition is terminally sterilized at 121°C for at least 15 minutes after filling in a sterilized syringe.
38. The process as claimed in claim 37, wherein the syringe is sterilized using about 47 kGy to about 50 kGy of X-ray radiation before filling it with composition comprising sugammadex or pharmaceutically acceptable salt thereof.
39. A process to prepare the prefilled syringe as claimed in claim 1, wherein the syringe is filled with sterile composition comprising sugammadex or its pharmaceutically acceptable salt and terminally sterilized at 121 °C for at least 15 minutes.
40. A method of use of the prefilled syringe as claimed in claim 1.
